PMV Pharmaceuticals Form 4: Tax-Related Insider Sale by CEO
Rhea-AI Filing Summary
PMV Pharmaceuticals, Inc. (PMVP) – Form 4 insider transaction
President & CEO David Henry Mack reported a sale of 58,411 common shares on 07/01/2025 at an average price of $1.0645 per share. The sale was executed under Rule S (open-market or private sale) and, according to the filing, was undertaken solely to cover tax obligations arising from the vesting of restricted stock units (Footnote 1).
After the transaction, Mack continues to own 536,133 shares directly. He also has indirect interests of 165,307 shares (Stinson 2021 Irrevocable Trust), 147,915 shares (Mack-Mulligan Revocable Trust) and 56,978 shares (Mack/Mulligan 2020 Irrevocable Descendants’ Trust), bringing his total reported beneficial position to 906,333 shares. No derivative securities were bought or sold, and there were no new options, warrants, or RSU transactions reported.
The sale represents roughly 10.9 % of Mack’s direct holdings and about 6.4 % of his total reported beneficial ownership. Because the disposition was for tax-withholding purposes, it does not necessarily signal a change in sentiment; nevertheless, investors often monitor any CEO share sales for potential insight into insider views of future prospects.
Positive
- CEO retains a large ownership stake of approximately 906,333 shares after the sale, maintaining alignment with shareholders.
- Sale purpose disclosed as tax-withholding from RSU vesting, suggesting it is administrative rather than sentiment-driven.
Negative
- Insider sale by the CEO can be perceived negatively, even if for tax reasons, and represents about 10.9 % of his direct holdings.
Insights
TL;DR: Small tax-related sale; CEO still retains ~900k shares—neutral signal.
The 58.4k-share disposition equals just over 6 % of David Mack’s aggregate ownership and was explicitly tied to RSU tax withholding. Such administrative sales are routine and generally carry limited informational value about future fundamentals. Importantly, Mack’s remaining stake exceeds 900k shares, aligning management with shareholder interests. The lack of accompanying derivative activity or multiple insiders selling supports a neutral impact assessment.
TL;DR: Transaction looks procedural; governance risk low.
The Form 4 cites tax obligations as the rationale, a standard practice permitted under company policies and Rule 10b5-1 protections. Mack continues to be both CEO and director, and the retained stake remains significant, preserving incentive alignment. No red flags such as pattern selling, option repricing, or simultaneous insider disposals appear. Consequently, I classify this filing as not materially impactful from a governance risk perspective.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 58,411 | $1.0645 | $62K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. Includes 15,528 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2025. The shares are held of record by the Stinson 2021 Irrevocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein. The shares are held of record by the Mack-Mulligan Revocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein. The shares are held of record by the Mack/Mulligan 2020 Irrevocable Descendants' Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.
